Faron Pharmaceuticals Oy (AIM:FARN)

London flag London · Delayed Price · Currency is GBP · Price in GBX
207.50
-7.50 (-3.49%)
Jul 11, 2025, 4:27 PM GMT+1
109.60%
Market Cap 232.31M
Revenue (ttm) n/a
Net Income (ttm) -21.44M
Shares Out 111.95M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,853
Average Volume 12,984
Open 210.00
Previous Close 215.00
Day's Range 202.50 - 220.00
52-Week Range 103.00 - 270.00
Beta 1.15
RSI 45.84
Earnings Date Aug 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 25
Stock Exchange London Stock Exchange AIM
Ticker Symbol FARN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data

At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...

4 days ago - IBTimes